# A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer

> **NCT06776770** · PHASE1,PHASE2 · RECRUITING · sponsor: **Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center** · enrollment: 52 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Adebrelimab

## Key facts

- **NCT ID:** NCT06776770
- **Lead sponsor:** Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-03
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06776770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06776770, "A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06776770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*